Literature DB >> 9047203

Secondary ischemia caused by venous or arterial occlusion shows differential effects on myocutaneous island flap survival and muscle ATP levels.

E M Hauge1, E Balling, T Hartmund, V E Hjortdal.   

Abstract

Ischemia-reperfusion injury is one of the major problems in reconstructive microsurgery. The ischemic insult may be due to an occlusion of either the artery or the vein. Clinical observations have suggested that flap survival is more sensitive to venous stasis than to arterial ischemia. The current study evaluated the viability of the myocutaneous rectus abdominis flap following secondary arterial or venous occlusion and its possible dependency on tissue metabolites and length of the preceding reperfusion period. Forty-eight bilateral 5 X 10 cm myocutaneous rectus abdominis flaps were elevated in 24 pigs and exposed to consecutive periods of primary ischemia (2 hours), reperfusion (1, 4, 8, and 12 hours), and secondary pedicle occlusion (6, 8, 10, 12, 14, or 16 hours) of arterial or venous origin. Muscle adenosine triphosphate (ATP) and glucose-6-phosphate (G6P) were assessed immediately after flap elevation, at the end of primary ischemia, after reperfusion, and at the end of secondary ischemia. Flap viability was assessed 5 days after the operation. Secondary venous occlusion resulted in reduced survival rates as compared with arterial occlusion (9 of 24 versus 20 of 24; p < 0.01), although the average ATP content was higher in flaps subjected to venous stasis [median (25 to 75) percentiles, 3.7 (1.7 to 7.1) micromol/gm protein] than in those subjected to arterial ischemia 1.2 (0.8 to 1.8 micromol/gm protein) (p < 0.01). During reperfusion, muscle ATP decreased from 28.5 (17.9 to 36.6) micromol/gm protein to 15.4 (7.4 to 24.9) micromol/gm protein (p < 0.01) and glucose-6-phosphate from 7.6 (4.1 to 11.6) micromol/gm protein to 1.0 (0.5 to 4.1) micromol/gm protein (p < 0.01). Still, flap survival following secondary arterial ischemia was improved by increasing the reperfusion time from 1 to 8 hours (p < 0.05). No effect of reperfusion time was seen on viability after venous stasis. In conclusion, despite poorer flap survival, venous stasis was less detrimental to tissue ATP level, suggesting that the continued inflow may have supplied substrates for glycolysis. Furthermore, the larger blood volume may have accumulated the glycolytic waste products. After reperfusion, the recovery of aerobic metabolism was far from complete, and cellular glycolytic substrates were nearly exhausted. However, prolongation of the reperfusion time preceding secondary arterial ischemia improved flap survival.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9047203     DOI: 10.1097/00006534-199703000-00032

Source DB:  PubMed          Journal:  Plast Reconstr Surg        ISSN: 0032-1052            Impact factor:   4.730


  4 in total

1.  Local cooling provides muscle flaps protection from ischemia-reperfusion injury in the event of venous occlusion during the early reperfusion period.

Authors:  Ryan S Diederich; Arian Mowlavi; Garth Meldrum; Brad Medling; Reuben A Bueno; Michael W Neumeister
Journal:  Hand (N Y)       Date:  2008-09-24

2.  Different patterns of intestinal response to injury after arterial, venous or arteriovenous occlusion in rats.

Authors:  Francisco Javier Guzmán-de la Garza; Carlos Rodrigo Cámara-Lemarroy; Gabriela Alarcón-Galván; Paula Cordero-Pérez; Linda Elsa Muñoz-Espinosa; Nancy Esthela Fernández-Garza
Journal:  World J Gastroenterol       Date:  2009-08-21       Impact factor: 5.742

3.  Ratio of Blood Glucose Level Change Measurement for Flap Monitoring.

Authors:  Ryo Karakawa; Hidehiko Yoshimatsu; Mitsunaga Narushima; Takuya Iida
Journal:  Plast Reconstr Surg Glob Open       Date:  2018-07-16

4.  Benefit of HSP90α intervention on ischemia-reperfusion injury of venous blood-congested flaps.

Authors:  Xiao-Ying Hu; Zhen-Yu Chen; Bin Zhang; Xiang-Feng Leng; Xiao-Jian Fan; Tao Liu
Journal:  Exp Ther Med       Date:  2016-05-09       Impact factor: 2.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.